DFMO inhibition of neuroblastoma tumorigenesis

• Published in: Cancer medicine (Malden, MA) Vol. 13; no. 9; pp. e7207 - n/a
• Main Authors: Gandra, Divya, Mulama, David H., Foureau, David M., McKinney, Kimberly Q., Kim, Elizabeth, Smith, Kaitlyn, Haw, Jason, Nagulapally, Abhinav, Saulnier Sholler, Giselle L.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.05.2024; John Wiley and Sons Inc; Wiley
• Subjects: Animal models; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; Apoptosis - drug effects; Biosynthesis; Carcinogenesis - drug effects; Cell culture; Cell cycle; Cell Cycle - drug effects; Cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Cell viability; Children & youth; Cytotoxicity; DFMO; Drug dosages; Eflornithine; Eflornithine - pharmacology; Eflornithine - therapeutic use; ELDA; Female; Gene amplification; Humans; Laboratories; Mathematical models; Medical prognosis; Metabolism; Mice; Neuroblastoma; Neuroblastoma - drug therapy; Neuroblastoma - metabolism; Neuroblastoma - pathology; neurosphere; Neurospheres; Penicillin; Polyamines; Proteins; S phase; Senescence; Statistical analysis; Tumor cell lines; Tumorigenesis; Tumors; xenograft; Xenograft Model Antitumor Assays; β-Galactosidase; United States > US; senescence; ELDA; xenograft; cell cycle; neuroblastoma; DFMO; neurosphere
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.7207

Background Most high‐risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event‐free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy. The effect of DFMO on cellular processes associated with neuroblastoma tumorigenesis needs further elucidation. Previous studies have shown cytotoxicity with IC50 values >5–15 mM, these doses are physiologically unattainable in patients, prompting further mechanistic studies at therapeutic doses. Methods We characterized the effect of DFMO on cell viability, cell cycle, apoptosis, neurosphere formation, and protein expression in vitro using five established neuroblastoma cell lines (BE2C, CHLA‐90, SHSY5Y, SMS‐KCNR, and NGP) at clinically relevant doses of 0, 50, 100, 500, 1000, and 2500 μM. Limiting Dilution studies of tumor formation in murine models were performed. Statistical analysis was done using GraphPad and the level of significance set at p = 0.05. Results There was not a significant loss of cell viability or gain of apoptotic activity in the in vitro assays (p > 0.05). DFMO treatment initiated G1 to S phase cell cycle arrest. There was a dose‐dependent decrease in frequency and size of neurospheres and a dose‐dependent increase in beta‐galactosidase activity in all cell lines. Tumor formation was decreased in xenografts both with DFMO‐pretreated cells and in mice treated with DFMO. Conclusion DFMO treatment is cytostatic at physiologically relevant doses and inhibits tumor initiation and progression in mice. This study suggests that DFMO, inhibits neuroblastoma by targeting cellular processes integral to neuroblastoma tumorigenesis at clinically relevant doses.